LONDON, Dec. 14, 2020 (GLOBE NEWSWIRE) — SpectrumX Healthcare Limited is delighted to announce the successful launch of new biosecurity measures at Saturday’s Joshua v Pulev heavyweight title clash. The fight saw the roll out of a new, high-capacity disinfection tunnel with a flow rate of 5,400 people per hour. The three-lane pods were used by the athletes, staff and press at Saturday’s event.
The SpectrumX tunnels are designed to work in real life conditions, allowing attendees at major public events such as Saturday’s fight, or Premier League football, to enter and exit stadia with little or no delay. SpectriPOD tunnels work by taking the concept of sanitising or washing hands and extending it out over the entire body. The pods deliver an ultra-fine mist of anti-viral and anti-microbial sanitising solution, Spectricept, capable of neutralising germs on hair, skin and clothing.
So far over 2,000 attendees at Matchroom events such as Saturday’s fight have passed through the SpectrumX pods. Not a single case of coronavirus infection has been reported at any of these events. The use of the tunnels at Saturday’s fight is just one part of a raft of safety measures, including temperature checks, coronavirus testing and the appropriate use of facemasks and social distancing designed to increase biosecurity at the event.
Damien Hancox, Chief Executive of SpectrumX Healthcare said: “We are delighted that Matchroom has once again agreed to use our technology at the event. This demonstrates the organisers’ commitment to provide the safest possible environment, and moves us one step closer to increasing to full capacity the number of fans allowed back into live sporting events.”
The use of the SpectrumX pods at Saturday’s fight is part of the development of a ‘Cleanzone’ concept designed to protect not only those people attending major events but also the wider community. The safety measures, including the use of the sanitisation tunnel, will provide the safest possible environment within the venue, dramatically reducing the possibility of cross infection from Covid-19 or any other virus. By insisting that attendees also pass through the SpectriPOD on departure, the system could also add an extra layer of security against any remaining infection being taken out into the wider community such as the surrounding transport networks.
SpectriPODs are the only sanitising tunnels in the world to use the patent-pending disinfectant, Spectricept. Spectricept is a 100% human safe, bio-compatiable, antiviral and antimicrobial formulation, derived from HOCL, which is found in human white blood cells. The patent-pending Spectricept formulation is the only formulation of HOCl which is effective in real life conditions, cutting through dirt and sweat to kill 99.99996% of all bacteria and viruses it comes into contact with, including on hair, skin and clothes.
Notes for editors
SpectrumX is a public health company whose aim is to bring us back together in a safe way. We are focused on using the best available technology to protect people by reducing the risk of cross infection, during the current pandemic and beyond. SpectrumX is the only company in the UK to have the license to use patent-pending disinfectant, Spectricept. Spectricept has undergone extensive scientific testing in the UK and USA, establishing its efficacy and safety. More information on the science behind Spectricept is available on request.
DropBox with more images of the SpectriPODs at Saturday’s event can be accessed here. For more information contact:
Jonathan Russell
07791 295766
jonathan.russell@spectrumx.com
www.spectrumx.com
Toronto, Ontario--(Newsfile Corp. - December 27, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…
RA'ANANA, Israel, Dec. 27, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), (NASDAQ:…
CHONGQING, China, Dec. 27, 2024 /PRNewswire/ -- BGM Group Ltd. (Stock Code: BGM) has successfully acquired…
MIAMI, Dec. 27, 2024 /PRNewswire/ -- Navigantis Inc. announced today the first successful neurovascular clinical cases…
Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without…
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the…